Eli Lilly’s profit doubled in the fourth quarter, propelled by its hot-selling diabetes and obesity treatments, and the drugmaker came out with a mostly better-than-expected 2025 forecast. Sales ...

One of the most important launches for Novartis in recent years is off with a bang. Following a broad FDA approval for the adjuvant treatment of HR-positive, HER2-negative early breast cancer in ...

These relatively new approvals join a lineup of several older medicines whose sales are still growing at a good clip, including immunosuppressant Taltz, cancer drug Verzenio, and fast-acting ...